Oral Presentation – First Author in ASCO/ESMO Meetings

  1. Oral Presentation, ESMO Congress 2025, Special Symposium: Exploiting homologous recombination alteration across the spectrum disease stages. Berlin, Germany. October 20, 2025
  2. Oral Presentation, 2025 Genitourinary Cancer Symposium (GU ASCO), TALAPRO-2: Overall Survival Result of Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Francisco, CA. February 13-15, 2025
  3. Oral Presentation, ESMO Congress 2024, Proffered Paper Session: Final Overall Survival Results: CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Barcelona, Spain. September 13-17, 2024.
  4. Oral Presentation, ESMO Congress 2024, Education session: T-cell engagers in prostate cancer (special symposium on What’s on the horizon for metastatic prostate cancer patients). Barcelona, Spain. September 14, 2024
  5. Oral Presentation, 2024 Genitourinary Cancer Symposium (GU ASCO), CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Franciso, CA. January 25-27, 2024
  6. Oral Presentation, ESMO Congress 2023, Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Madrid, Spain. October 20-24, 2023
  7. Oral Presentation, 2023 ASCO Annual Meeting,When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer. Chicago, IL. June 2-6, 2023
  8. Oral Presentation, 2023 Genitourinary Cancer Symposium (GU ASCO), TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Francisco, CA. February 15-17, 2023
  9. Oral Presentation, ESMO Congress 2021, Proffered Paper session. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study. Paris, France, September 16-21, 2021
  10. Oral Presentation, 2021 ASCO Annual Meeting. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Chicago, IL. June 4-8, 2021
  11. Oral Presentation, 2020 Genitourinary Cancer Symposium (GU ASCO). Time to Second Progression (PFS2) in Patients from TITAN with Metastatic Castration-Sensitive Prostate Cancer by First Subsequent Therapy (Hormonal vs Taxane). San Francisco, CA. February 13-15, 2020
  12. Oral Presentation, 2019 ASCO Annual Meeting – Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma. Chicago, IL. May 31-June 4, 2019
  13. Oral Presentation, 2016 Genitourinary Cancer Symposium (GU ASCO). Novel Immunotherapeutic Approaches and Biomarkers in Renal Cell Carcinoma (RCC). San Francisco, CA. January 7-9, 2016

Follow me on Twitter